Biotech and Pharma Industry News | BioPharma Dive
WEB23andMe’s independent board directors resign. In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Radiopharmaceuticals for cancer: Making radiation precise
WEBAug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
Seagen’s cancer drug succeeds in ‘must-win’ trial
WEBSep 22, 2023 · A combination of cancer drugs from Seagen and Merck & Co. has shown early success in a large clinical trial, results that help confirm the pairing’s ability to treat a wide range of bladder cancer patients. The trial has enrolled around 1,000 participants who have urothelial cancer that’s grown or spread to other parts of the body, and who ...
Biohaven starts life as new company following Pfizer buyout
WEBOct 5, 2022 · On Tuesday, Biohaven Ltd. officially launched as a newly independent company, spun out of its former parent as part of Pfizer’s $11.6 billion acquisition, which closed on Oct. 3. Led by the same CEO, Vlad Coric, and publicly traded under the same stock ticker, the new Biohaven retains a pipeline of experimental medicines for a range …
J&J spinoff Kenvue raises $3.8 billion in year’s largest IPO
WEBMay 4, 2023 · Dive Insight: The $3.8 billion haul represents the largest IPO since electric car marker Rivian raised $11.9 billion in November 2021 and could boost the struggling market for public offerings in the U.S.. With the Kenvue spinoff and an offering from the biotechnology company Acelyrin due to price Thursday night, IPO proceeds this year are …
Pharma News | BioPharma Dive
WEB5 days ago · Novo sinks on obesity drug results; Sanofi reveals anticipated MS data. A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged. By BioPharma Dive staff •Sept. 20, 2024.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high …
A decade later, biotech’s CRISPR revolution is still going strong
WEBOct 11, 2023 · A cell and an injection needle are projected onto a screen during a CRISPR/Cas9 experiment in Berlin, Germany, on May 22, 2018. A research paper published a decade ago touched off a biomedical revolution that has made careers, spawned companies and drawn billions of dollars of investment. By the end of the year, …
10 clinical trials to watch in the second half of 2022
WEBJul 5, 2022 · The second half of the year could bring similarly important results from clinical trials testing drugs for Alzheimer’s disease, cancer and vision loss. Positive data, if it comes, might give biotech a needed boost. Here are 10 trials to watch: Companies: Eisai, Biogen. Disease: Alzheimer's. Treatment type:
Incyte, branching out in dermatology, to buy startup Villaris
WEBOct 3, 2022 · Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for the skin disease vitiligo, the companies announced Monday. It’s Incyte’s first whole company acquisition.